Is Acalabrutinib a targeted drug?

Acalabrutinib (Acalabrutinib) belongs to the category of targeted drugs. As a Brutinib (BTK) inhibitor, its design and mechanism of action aim to selectively interfere with specific signaling pathways within tumor cells to inhibit the growth and spread of tumors derived from B cells such as leukemia and lymphoma.

BTKis a key enzyme in the B cell receptor signaling pathway and participates in the activation and proliferation of B cells. Abnormally activated B cell signaling pathways are closely related to the occurrence and development of various B cell malignant tumors. Acotinib blocks the conduction of this signaling pathway by selectively binding to BTK and inhibiting its activity, thereby hindering the growth, survival and spread of tumor cells.

Compared with traditional chemotherapy drugs, targeted drugs have stronger specificity and more precisely act on tumor cells or their surrounding microenvironment, reducing the adverse effects on normal cells. This precision is achieved by understanding the molecular signatures within cancer cells and designing drugs to interfere with these specific molecular mechanisms.

The targeting effect of acotinib allows it to show significant efficacy in the treatment of specific types ofB cell lymphoma and leukemia, while reducing the toxic and side effects associated with traditional treatments. However, it is worth noting that targeted drugs may still cause some adverse reactions, so patients need to be closely monitored during use and adjusted according to the guidance of their doctor. Overall, acotinib represents an important advance in the field of targeted therapy, providing a more effective and precise option for the treatment of certain malignant tumors.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.